GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

GSK GSK-0.10%decrease; red down pointing triangle shares topped the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S ...

GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology market and expanding its preventive healthcare through adult vaccines.

With Gilead Sciences sprinting to a likely approval next year for its long-acting pre-exposure prophylaxis (PrEP) drug for HIV, the California company has a chance to one-up GSK. While the British ...

GSK GSK0.13%increase ... allegations its discontinued heartburn medicine Zantac causes cancer. The British pharmaceutical giant said Wednesday that it had struck agreements with 10 plaintiff ...

Leverage fair value analysis to evaluate the market value of stocks enabling more informed investment decisions.

GSK has received a recommendation from the European Medicines Agency’s human medicines committee for a single-vial, fully liquid presentation of its meningococcal vaccine Menveo. The new presentation, ...

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals.

Learn More. The GSK (LSE: GSK) share price is a nightmare and there’s little sign of respite for long-suffering investors. Shares in the FTSE 100 pharmaceutical giant now trade 10.18% lower than ...

People living with HIV and people with potential exposure to HIV in China are expected to leverage more of ... treatment of the disease as the global pharmaceutical company aims to further expand ...